Anti-infectives specialist Xellia Pharmaceuticals has announced becoming a member of Medicines for Europe, effective from the start of 2021. The company has committed to help the off-patent industry association to secure the European pharmaceutical supply chain and improve access for patients.
Xellia CEO and president Carl-Åke Carlsson said “acceptance into Medicines for Europe is great recognition of our work and will enable Xellia to unite with like-minded companies also